Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): A randomized,...

Area of Science:

• Cardiology
• Immunology
• Pharmacology

Background:

• Acute myocardial infarction (AMI) intensity correlates with poor prognosis.
• Interleukin-1 (IL-1), a pro-inflammatory cytokine, contributes to adverse cardiac remodeling and heart failure (HF) post-AMI.
• Targeting IL-1 may mitigate adverse outcomes following ST-segment elevation myocardial infarction (STEMI).

Purpose of the Study:

• To evaluate the safety and efficacy of IL-1 receptor antagonist (anakinra) in blocking IL-1 during the acute phase of STEMI.
• To assess anakinra's impact on cardiac remodeling, function, and major adverse cardiovascular outcomes up to 12 months post-STEMI.
• To determine if anakinra reduces the inflammatory response, measured by C-reactive protein levels, in STEMI patients.

Main Methods:

• Phase 2, multicenter, double-blinded, randomized, placebo-controlled trial (VCU-ART3).
• 99 STEMI patients within 12 hours of symptom onset received anakinra (100 mg once or twice daily) or placebo for 14 days.
• Exclusion criteria included history of severe HF, valvular/kidney disease, active infection, malignancy, or autoimmune diseases.

Main Results:

• Primary efficacy endpoint: difference in C-reactive protein area under the curve (admission to day 14) between anakinra and placebo groups (P<0.025).
• Secondary endpoints: cardiac remodeling and function assessed by echocardiography up to 12 months.
• Tertiary endpoints: major adverse cardiovascular outcomes including cardiovascular death, MI, revascularization, and new-onset HF.

Conclusions:

• The VCU-ART3 trial will provide critical data on the safety and efficacy of IL-1 blockade in STEMI.
• Findings may establish anakinra as a novel therapeutic strategy to improve outcomes after STEMI.
• Understanding IL-1's role in STEMI pathophysiology could lead to targeted treatments for preventing heart failure and improving prognosis.